Data from Phase IIb AIPAC Trial of Eftilagimod Alpha Shows Promise

Immutep reported positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha and paclitaxel in HER2-negative, HR-positive metastatic breast cancer (MBC).

Source: CancerNetwork - April 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news